The regulation of cell morphology is a dynamic process under the control of multiple protein complexes acting in a coordinated manner. Phosphoinositide 3-kinases (PI3K) and their lipid products are widely involved in cytoskeletal regulation by interacting with proteins regulating RhoGTPases. Class II PI3K isoforms have been implicated in the regulation of the actin cytoskeleton, although their exact role and mechanism of action remain to be established. In this report, we have identified Dbl, a Rho family guanine nucleotide exchange factor (RhoGEF) as an interaction partner of PI3KC2β. Dbl was co-immunoprecipitated with PI3KC2β in NIH3T3 cells and cancer cell lines. Over-expression of Class II phosphoinositide 3-kinase PI3KC2β in NIH3T3 fibroblasts led to increased stress fibres formation and cell spreading. Accordingly, we found high basal RhoA activity and increased serum response factor (SRF) activation downstream of RhoA upon serum stimulation. In contrast, the dominant-negative form of PI3KC2β strongly reduced cell spreading and stress fibres formation, as well as SRF response. Platelet-derived growth factor (PDGF) stimulation of wild-type PI3KC2β over-expressing NIH3T3 cells strongly increased Rac and c-Jun N-terminal kinase (JNK) activation, but failed to show similar effect in the cells with the dominant-negative enzyme. Interestingly, epidermal growth factor (EGF) and PDGF stimulation led to increased extracellular signal-regulated kinase (Erk) and Akt pathway activation in cells with elevated wild-type PI3KC2β expression. Furthermore, increased expression of PI3KC2β protected NIH3T3 from detachment-dependent death (anoikis) in a RhoA-dependent manner. Taken together, these findings suggest that PI3KC2β modulates the cell morphology and survival through a specific interaction with Dbl and the activation of RhoA.
References
[1]
Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, et al. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615–675.
[2]
Wymann MP, Bjorklof K, Calvez R, Finan P, Thomast M, et al. (2003) Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem Soc Trans 31: 275–280.
[3]
Sasaki T, Suzuki A, Sasaki J, Penninger JM (2002) Phosphoinositide 3-kinases in immunity: lessons from knockout mice. J Biochem 131: 495–501.
[4]
DiNitto JP, Cronin TC, Lambright DG (2003) Membrane recognition and targeting by lipid-binding domains. Sci STKE 2003: re16.
[5]
Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606–619.
[6]
Schmidt A, Hall A (2002) Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 16: 1587–1609.
[7]
Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, et al. (1998) Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem 273: 33082–33090.
[8]
Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, et al. (1997) Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 326 (Pt 1): 139–147.
[9]
Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, et al. (2000) Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol 20: 3817–3830.
[10]
Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD, et al. (2002) Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. Embo J 21: 5097–5108.
[11]
Falasca M, Hughes WE, Dominguez V, Sala G, Fostira F, et al. (2007) The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem 282: 28226–28236.
[12]
Wheeler M, Domin J (2001) Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol 21: 6660–6667.
[13]
Brown RA, Domin J, Arcaro A, Waterfield MD, Shepherd PR (1999) Insulin activates the alpha isoform of class II phosphoinositide 3-kinase. J Biol Chem 274: 14529–14532.
[14]
Gaidarov I, Smith ME, Domin J, Keen JH (2001) The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell 7: 443–449.
Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, et al. (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 169: 789–799.
[17]
Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, et al. (2006) Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 17: 3729–3744.
[18]
Domin J, Harper L, Aubyn D, Wheeler M, Florey O, et al. (2005) The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. J Cell Physiol 205: 452–462.
[19]
Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, et al. (2003) Cell migration: integrating signals from front to back. Science 302: 1704–1709.
[20]
Cain RJ, Ridley AJ (2009) Phosphoinositide 3-kinases in cell migration. Biol Cell 101: 13–29.
[21]
Velichkova M, Juan J, Kadandale P, Jean S, Ribeiro I, et al. (2010) Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions. J Cell Biol 190: 407–425.
[22]
Seok YM, Azam MA, Okamoto Y, Sato A, Yoshioka K, et al. (2010) Enhanced Ca2+-dependent activation of phosphoinositide 3-kinase class IIalpha isoform-Rho axis in blood vessels of spontaneously hypertensive rats. Hypertension 56: 934–941.
[23]
Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21: 247–269.
[24]
Nobes CD, Hall A (1999) Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144: 1235–1244.
[25]
Etienne-Manneville S, Hall A (2001) Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 106: 489–498.
[26]
Eva A, Aaronson SA (1985) Isolation of a new human oncogene from a diffuse B-cell lymphoma. Nature 316: 273–275.
[27]
Eva A, Vecchio G, Diamond M, Tronick SR, Ron D, et al. (1987) Independently activated dbl oncogenes exhibit similar yet distinct structural alterations. Oncogene 1: 355–360.
[28]
Ron D, Tronick SR, Aaronson SA, Eva A (1988) Molecular cloning and characterization of the human dbl proto-oncogene: evidence that its overexpression is sufficient to transform NIH/3T3 cells. EMBO J 7: 2465–2473.
[29]
Ron D, Graziani G, Aaronson SA, Eva A (1989) The N-terminal region of proto-dbl down regulates its transforming activity. Oncogene 4: 1067–1072.
[30]
Graziani G, Ron D, Eva A, Srivastava SK (1989) The human dbl-proto-oncogene product is a cytoplasmic phosphoprotein which is associated with the cytoskeletal matrix. Oncogene 4: 823–829.
[31]
Kauppinen KP, Duan F, Wels JI, Manor D (2005) Regulation of the Dbl proto-oncogene by heat shock cognate protein 70 (Hsc70). J Biol Chem 280: 21638–21644.
[32]
Kamynina E, Kauppinen K, Duan F, Muakkassa N, Manor D (2007) Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation. Mol Cell Biol 27: 1809–1822.
[33]
Bi F, Debreceni B, Zhu K, Salani B, Eva A, et al. (2001) Autoinhibition mechanism of proto-Dbl. Mol Cell Biol 21: 1463–1474.
[34]
Zheng Y (2001) Dbl family guanine nucleotide exchange factors. Trends Biochem Sci 26: 724–732.
[35]
Rossman KL, Der CJ, Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6: 167–180.
[36]
Buchsbaum RJ (2007) Rho activation at a glance. J Cell Sci 120: 1149–1152.
[37]
Scita G, Tenca P, Frittoli E, Tocchetti A, Innocenti M, et al. (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs. Embo J 19: 2393–2398.
[38]
Innocenti M, Frittoli E, Ponzanelli I, Falck JR, Brachmann SM, et al. (2003) Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J Cell Biol 160: 17–23.
[39]
Posern G, Sotiropoulos A, Treisman R (2002) Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. Mol Biol Cell 13: 4167–4178.
[40]
Das M, Scappini E, Martin NP, Wong KA, Dunn S, et al. (2007) Regulation of neuron survival through an intersectin-phosphoinositide 3′-kinase C2beta-AKT pathway. Mol Cell Biol 27: 7906–7917.
[41]
Broome MA, Hunter T (1996) Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. J Biol Chem 271: 16798–16806.
Hill CS, Wynne J, Treisman R (1995) The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81: 1159–1170.
[44]
Arsenian S, Weinhold B, Oelgeschlager M, Ruther U, Nordheim A (1998) Serum response factor is essential for mesoderm formation during mouse embryogenesis. Embo J 17: 6289–6299.
[45]
Miralles F, Posern G, Zaromytidou AI, Treisman R (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113: 329–342.
[46]
van den Heuvel AP, Schulze A, Burgering BM (2005) Direct control of caveolin-1 expression by FOXO transcription factors. Biochem J 385: 795–802.
[47]
Burgering BM, Medema RH (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73: 689–701.
[48]
Engelman JA, Zhang X, Galbiati F, Volonte D, Sotgia F, et al. (1998) Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Genet 63: 1578–1587.
[49]
Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, et al. (1997) Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 272: 16374–16381.
[50]
Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, et al. (1998) Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. Embo J 17: 6633–6648.
Whitehead IP, Campbell S, Rossman KL, Der CJ (1997) Dbl family proteins. Biochim Biophys Acta 1332: F1–23.
[53]
Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T (2001) Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner. Biochem Biophys Res Commun 284: 470–477.
[54]
Kato J, Kaziro Y, Satoh T (2000) Activation of the guanine nucleotide exchange factor Dbl following ACK1-dependent tyrosine phosphorylation. Biochem Biophys Res Commun 268: 141–147.
[55]
Galisteo ML, Yang Y, Urena J, Schlessinger J (2006) Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A 103: 9796–9801.
[56]
Russo C, Gao Y, Mancini P, Vanni C, Porotto M, et al. (2001) Modulation of oncogenic DBL activity by phosphoinositol phosphate binding to pleckstrin homology domain. J Biol Chem 276: 19524–19531.
[57]
Hall A, Nobes CD (2000) Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos Trans R Soc Lond B Biol Sci 355: 965–970.
[58]
Jiang K, Sun J, Cheng J, Djeu JY, Wei S, et al. (2004) Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24: 5565–5576.
[59]
Coleman ML, Olson MF (2002) Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9: 493–504.
[60]
Perona R, Esteve P, Jimenez B, Ballestero RP, Ramon y Cajal S, et al. (1993) Tumorigenic activity of rho genes from Aplysia californica. Oncogene 8: 1285–1292.
[61]
Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374: 457–459.
[62]
Qiu RG, Chen J, McCormick F, Symons M (1995) A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 92: 11781–11785.
[63]
Liu Z, Sun C, Zhang Y, Ji Z, Yang G (2010) Phosphatidylinositol 3-kinase-C2beta inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma. J Int Med Res 39: 1319–1332.
